Please login to the form below
protease inhibitor
This page shows the latest protease inhibitor news and features for those working in and with pharma, biotech and healthcare.
Shionogi’s antiviral COVID-19 treatment meets phase 3 primary endpoint
Ensitrelvir reduced the time taken to resolve five key symptoms. Shionogi’s ensitrelvir fumaric acid (ensitrelvir) – an investigational protease inhibitor being evaluated as an antiviral treatment for COVID-19 – demonstrated a
Latest news
-
Enanta takes legal action against Pfizer over Paxlovid patent infringement
use of a coronavirus 3CL protease inhibitor claimed in the ‘953 patent”.
-
Pfizer agrees to supply UNICEF with up to 4 million courses of oral COVID-19 treatments
Paxlovid is a coronavirus main protease inhibitor – also known as SARS-CoV-2 3CL protease inhibitor – therapy.
-
Emergency use of Paxlovid allowed in Europe
Paxlovid is an orally administered, investigational SARS-CoV-2 protease inhibitor antiviral therapy. ... Paxlovid, however, works intracellularly on the protease of the SARS-CoV-2 virus by inhibiting viral replication,” said Pfizer.
-
US government to pay $5.3bn for Pfizer‘s Paxlovid
If approved by the FDA, the US government will purchase 10 million courses of Pfizer’s anti-COVID protease inhibitor antiviral therapy, Paxlovid, this year and into 2022. ... Paxlovid is a combination of PF-07321332 and ritonavir; PF-07321332 blocks
-
Pfizer's oral antiviral Paxlovid significantly cuts risk of severe COVID-19
A protease inhibitor, PF-07321332 is designed to block replication of SARS-CoV-2 while co-administration of the antiretroviral ritonavir – best known as an HIV treatment in HAART (highly active ... Merck’s Lagevrio (molnupiravir) -3CL protease
More from news
Approximately 2 fully matching, plus 83 partially matching documents found.
Latest Intelligence
-
Forging a path in specialty care
Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA
-
Pharma deals in May 2015
The agreement covers ACH 3102, ACH 3422 and sovaprevir. The intention is to trial a combination of ACH 3102 with a NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase ... inhibitor. ACH 3102 has been granted fast track designation by the FDA.
-
Deal Watch table for June 2013
1, 000. Aragon Pharmaceuticals / J&J. Acquisition. Includes ARN 509 (second generation androgen receptor signalling inhibitor) for castration-resistant prostate cancer (phase II). ... BL8030, second generation protease inhibitor in development for
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
